Patent US4005200A successfully refreshed from Google Patents.
US4005200A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for improving the maturity of the parturient canal and the sensitivity to oxytocin
Assignee: Kanebo Ltd
•
Filing: 1975-07-17
•
Granted: 1977-01-25
•
Expires: 1995-07-17
Abstract
Abstract A new use of dehydroepiandrosterone sulfate or its salt as a parturient canal conditioning agent is disclosed. The maturity of the parturient canal and the sensitivity of uterine musculature to oxytocin are improved resulting in normal parturition by administering to a pregnant human subject at the 37th to 39th week of pregnancy a therapeutically effective amount of dehydroepiandrosterone sulfate or its pharmaceutically acceptable salts such as the sodium salt.
Inventors
- 👤 Isamu Utsumi
- 👤 Tomio Endo
- 👤 Tadaaki Kamata
- 👤 Masayasu Ando
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 19:46
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/56; A61K31/565; A61P; A61P13/00; A61P13/02; A61P15/00; C; C07; C07J; C07J31/00; C07J31/006
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
46 words
A method for improving the maturity of parturient canal and the sensibility of uterine musculature to oxytocin, which comprises administering to a living pregnant human a therapeutically effective amount of dehydroepiandrosterone sulfate or a pharmaceutically acceptable salt thereof at the 37th to 39th week of pregnancy.
Claim 2
Independent Claim
46 words
A method for improving the maturity of parturient canal and the sensibility of uterine musculature to oxytocin, which comprises administering to a living pregnant human a therapeutically effective amount of dehydroepiandrosterone sulfate or a pharmaceutically acceptable salt thereof at the 37th to 39th week of pregnancy.
Claim 3
Dependent Claim
13 words
The method according to claim 1, wherein dehydroepiandrosterone sulfate sodium salt is administered.
Claim 4
Dependent Claim
20 words
The method according to claim 2, wherein dehydroepiandrosterone sulfate sodium salt is administered at a dose of 50mg. to 500mg.
Claim 5
Dependent Claim
13 words
The method according to claim 2, wherein the sodium salt is administered orally.
Claim 6
Dependent Claim
13 words
The method according to claim 2, wherein the sodium salt is administered parenterally.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-01-25 | 1980-07-26 | 1981-01-25 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-01-25 | 1984-07-26 | 1985-01-25 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-01-25 | 1988-07-26 | 1989-01-25 | $7700.00 | Window Closed / Lapsed |